5 Stocks With Big Insider Buying
Synta Pharmaceuticals
One stock in the health care complex whose insiders have snapped up a large amount of shares of is Synta Pharmaceuticals (SNTA), a biopharmaceutical firm focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Insiders are buying into strength here since this stock is up over 47% in the last three months.
Synta Pharmaceuticals has a market cap of $224.82 million and an enterprise value of $190.47 million. This stock trades at a price-to-sales of 27.36 and a price-to-book of 9.13. Its estimated growth rate for this year is -18.3%, and for next year it's pegged at 6.4%. This is a cash-rich company, with a total cash position on its balance sheet of $50.66 million and total debt of $16.8 million.
A director and beneficial owner just bought 1.1 million shares, or close to $5 million worth of stock, at $4.40 per share. From a technical standpoint, SNTA is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock recently bounced off its 50-day at $4.21 and its now moving back above its 200-day of $4.50 a share. Shares of SNTA are also starting to enter a gap down zone between $5 and $4.26 a share. If you're bullish SNTA, I would look to be a buyer of this stock if it can manage to close back above its 200-day moving average of $4.50 on solid volume. Look for volume that registers near or well above its three-month average action of 216,222 shares. If we get that action, then this stock has a good chance to run back towards its nearest overhead resistance levels at $5.15 to $5.23 a share. I would then add to any long positions if those levels are taken out with volume. I would use a mental stop just below near-term support at $4.44, or the 50-day at $4.21 if you want to give it more room. Synta is rated D- sell by TheStreet Ratings.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
